US · Healthcare · Drug Manufacturers - General
EPS came in at 0.19 against a street estimate of 0.27 — a miss of 29.6%.
Analysts rate Grifols SA ADR a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $10.87.
| Fund | Stake |
|---|---|
| Brandes Investment Partners & Co | 5.56% |
| Capital World Investors | 3.37% |
| Permian Investment Partners | 2.90% |
| Black Creek Investment Management Inc | 1.23% |
| Bank of America Corp | 0.96% |
| Millennium Management LLC | 0.64% |
| Flat Footed LLC | 0.64% |
| HHG PLC | 0.48% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Grifols announced changes to its Board of Directors following an extraordinary meeting held on 29 July 2026. • Iñigo Sánchez- | 2026-07-30 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • H1 2026 revenue was €3,574 million, up 2.6% at constant currency (cc). • Adjusted EBITDA was €854 million, up 2.4% cc. The adjust | 2026-07-29 |
| Current report (6-K) · Q2 2026 OTHER NOTABLE POINTS • Grifols’ Board of Directors acknowledged the resignation of Enriqueta Felip Font, effective 19 June 2026, from the Board and t | 2026-06-22 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • Grifols’ Ordinary General Shareholders’ Meeting approved the company’s audited individual and consolidated 2025 accounts and most | 2026-06-18 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Grifols reported 2025 net revenue of €7,524 million, up 4.3% from €7,212 million in 2024. • On a constant-currency basis, net rev | 2026-04-17 |
| Annual report FY2024 (20-F) | 2025-04-11 |
| Annual report FY2023 (20-F) | 2024-04-19 |
| Annual report FY2022 (20-F) | 2023-04-18 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.09 / share ex-date Jul 2, 2026 · pay Jul 9, 2026 | 2026-07-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Grifols SA ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.